PARP Inhibition for Gliomas (PI-4G or π4g)

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT05297864
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Niraparib — DRUG
    The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.

Study Details

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

Key Dates

First listed
Mar 28, 2022
Start date
Jun 9, 2022
Status verified
May 2025
Primary completion
Nov 14, 2023
Completion
Feb 6, 2024

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Niraparib Treatment
    Patients will be treated with individualized starting dose of Niraparib.

Primary Outcome Measure

Number of Patients Who Experience Adverse Events [ Time Frame: Up to 17 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stephenson Cancer CenterOklahoma CityOklahoma73104-

Find similar trials in Oklahoma City, OK

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials
By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Stephenson Cancer Center· Oklahoma City, OK

Related Studies